CNTX vs. KRRO, INMB, TVGN, VYGR, ELDN, INBX, ACIU, DMAC, BTMD, and SOPH
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Korro Bio (KRRO), INmune Bio (INMB), Tevogen Bio (TVGN), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), AC Immune (ACIU), DiaMedica Therapeutics (DMAC), biote (BTMD), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry.
Context Therapeutics vs.
Korro Bio (NASDAQ:KRRO) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Korro Bio's return on equity of -50.25% beat Context Therapeutics' return on equity.
Korro Bio has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500.
13.2% of Korro Bio shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 5.4% of Korro Bio shares are held by company insiders. Comparatively, 3.0% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Korro Bio had 6 more articles in the media than Context Therapeutics. MarketBeat recorded 26 mentions for Korro Bio and 20 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.70 beat Korro Bio's score of 0.40 indicating that Context Therapeutics is being referred to more favorably in the news media.
Korro Bio currently has a consensus target price of $142.57, suggesting a potential upside of 599.57%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 612.91%. Given Context Therapeutics' higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Korro Bio.
Context Therapeutics has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
Korro Bio received 3 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Korro Bio an outperform vote while only 76.67% of users gave Context Therapeutics an outperform vote.
Summary
Korro Bio beats Context Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Context Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CNTX) was last updated on 3/26/2025 by MarketBeat.com Staff
